OrbiMed’s Verona Pharma VRNA Stock Holding History

OrbiMed’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,861,801	Closed	-$41.4M	–	133
2024 Q2	$41.4M	Sell	2,861,801 -536,266	-16%	-$7.83M	0.82%	39
2024 Q1	$54.7M	Sell	3,398,067 -379,711	-10%	-$6.57M	1%	32
2023 Q4	$75.1M	Hold	3,777,778	–	–	1.5%	22
2023 Q3	$61.6M	Hold	3,777,778	–	–	1.31%	26
2023 Q2	$79.9M	Sell	3,777,778 -482,913	-11%	-$10.3M	1.45%	24
2023 Q1	$85.6M	Sell	4,260,691 -311,598	-7%	-$6.73M	1.68%	17
2022 Q4	$119M	Sell	4,572,289 -1,122,552	-20%	-$14.9M	2.29%	11
2022 Q3	$58.2M	Hold	5,694,841	–	–	1.08%	35
2022 Q2	$23.9M	Hold	5,694,841	–	–	0.43%	56
2022 Q1	$28.4M	Hold	5,694,841	–	–	0.46%	55
2021 Q4	$38.3M	Hold	5,694,841	–	–	0.49%	58
2021 Q3	$31.2M	Hold	5,694,841	–	–	0.34%	77
2021 Q2	$37.2M	Hold	5,694,841	–	–	0.38%	71
2021 Q1	$47.6M	Hold	5,694,841	–	–	0.45%	65
2020 Q4	$39.9M	Hold	5,694,841	–	–	0.35%	68
2020 Q3	$35.5M	Buy	5,694,841 +4,444,445	+355%	+$30.7M	0.45%	62
2020 Q2	$5.85M	Hold	1,250,396	–	–	0.08%	116
2020 Q1	$5.15M	Hold	1,250,396	–	–	0.09%	105
2019 Q4	$7.19M	Hold	1,250,396	–	–	0.1%	90
2019 Q3	$5.71M	Hold	1,250,396	–	–	0.11%	90
2019 Q2	$6.38M	Hold	1,250,396	–	–	0.1%	104
2019 Q1	$8.13M	Hold	1,250,396	–	–	0.13%	93
2018 Q4	$12.1M	Hold	1,250,396	–	–	0.22%	82
2018 Q3	$15.6M	Hold	1,250,396	–	–	0.19%	97
2018 Q2	$17.1M	Hold	1,250,396	–	–	0.2%	99
2018 Q1	$25M	Hold	1,250,396	–	–	0.31%	73
2017 Q4	$14.8M	Buy	1,250,396 +583,730	+88%	+$7.58M	0.19%	87
2017 Q3	$10.2M	Hold	666,666	–	–	0.1%	107
2017 Q2	$7.77M	Buy	+666,666	New	+$8.83M	0.08%	105

Other funds holding VRNA

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

OrbiMed's VRNA Position: Q3 2024 in Review

OrbiMed sold out of Verona Pharma (VRNA) in Q3 2024, closing a stake of 2,861,801 shares — an estimated $41.4M sold.

OrbiMed first reported a position in VRNA in Q2 2017 and held it in 29 quarters. The position peaked at $119M in Q4 2022. 150 funds tracked by Wall St. Rank hold VRNA as of Q3 2024.

OrbiMed reported no remaining Verona Pharma position as of Q3 2024 after selling out during the quarter.
OrbiMed sold 2,861,801 Verona Pharma shares in Q3 2024, an estimated $41.4M.
OrbiMed first reported a position in Verona Pharma in Q2 2017 and held it in 29 quarters.
OrbiMed's Verona Pharma position peaked at $119M in Q4 2022.
150 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2024.

Based on OrbiMed's 13F filing for Q3 2024, filed 14 Nov 2024.